Concord Drugs Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 14, 2026

Key Highlights

The Latest Trading Price of Concord Drugs Ltd is ₹ 79.41 as of 14 May 15:30 . The P/E Ratio of Concord Drugs Ltd changed from 15.9 on March 2022 to 91.4 on March 2025 . This represents a CAGR of 54.84% over 4 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 38.5 on March 2021 to 16.9 on March 2025 . This represents a CAGR of -15.18% over 5 years The Market Cap of Concord Drugs Ltd changed from ₹ 25.36 crore on March 2022 to ₹ 31.08 crore on March 2025 . This represents a CAGR of 5.22% over 4 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 75095 crore on March 2021 to ₹ 95465 crore on March 2025 . This represents a CAGR of 4.92% over 5 years The revenue of Concord Drugs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 16.99 crore. This represent the decline of -100% The revenue of Dr Reddys Laboratories Ltd for the Mar '26 is ₹ 8026 crore as compare to the Dec '25 revenue of ₹ 9024 crore. This represent the decline of -11.06% The ebitda of Concord Drugs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0.94 crore. This represent the decline of -100% The ebitda of Dr Reddys Laboratories Ltd for the Mar '26 is ₹ 862.5 crore as compare to the Dec '25 ebitda of ₹ 2158 crore. This represent the decline of -60.04% The net profit of Concord Drugs Ltd changed from ₹ 0.03 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1392 crore to ₹ 221.3 crore over 8 quarters. This represents a CAGR of -60.13% The Dividend Payout of Concord Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 19.03 % on March 2021 to 12.47 % on March 2025 . This represents a CAGR of -8.11% over 5 years .

About Concord Drugs Ltd

Concord Drugs Limited, established in 1995, is amongst the respected pharmaceutical companies in India for manufacturing of Finished Pharmaceutical Formulations like Injectables (Small Volume parenterals, Dry Syrup powder) ,Tissue Bio-Adhesive, tablets, capsules and ophthalmic preparations and Ready-to-fill Pellets. The principal activity of the Company is to manufacture licensed drugs based on the formulations approved.
The Company has two manufacturing facilities license issued by The Government of Andhra Pradesh, Drugs Control Administration, and Hyderabad.
State of the art technology having dedicated manufacturing facilities for Liquid Injections, Dry powder Injections and Ready-to-fill Pellets ensures the highest level of process integrity and product quality. The Company started with Finished Pharmaceutical Formulations and then diversified into Ready-to-fill Pellets, to provide customers with end-to-end solution to their various pharmaceutical product needs to commercial contract drug manufacturing.

About Dr Reddys Laboratories Ltd

Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's portfolio of products and services include Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
Dr. Reddy's operates in markets across the globe.
Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

FAQs for the comparison of Concord Drugs Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Concord Drugs Ltd or Dr Reddys Laboratories Ltd?

Market cap of Concord Drugs Ltd is 104 Cr while Market cap of Dr Reddys Laboratories Ltd is 108,739 Cr

What are the key factors driving the stock performance of Concord Drugs Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Concord Drugs Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Concord Drugs Ltd and Dr Reddys Laboratories Ltd?

As of May 14, 2026, the Concord Drugs Ltd stock price is INR ₹79.41. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1302.8.

How do dividend payouts of Concord Drugs Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Concord Drugs Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.